<?xml version="1.0" encoding="UTF-8"?>
<p id="p0130">For scale-up of hepatitis B prevention through vaccination, GAVI, a large global innovative financing mechanism(23), is ideally placed. To date, GAVI has disbursed US$11.2 billion for vaccines across 76 LMICs, including hepatitis B vaccination since 2000. Importantly, GAVI has recently announced the addition of birth dose vaccine in its 2021-2025 Vaccine Investment Strategy to prevent mother to child transmission(28). This will be critical to improve the implementation of birth dose vaccination in low-income countries where the need for timely birth dose vaccination of infants is greatest due to high population prevalence, sub-optimal childhood vaccination rates and lack of hepatitis B immunoglobulin availability for mothers living with hepatitis B infection (
 <xref rid="bib2" ref-type="bibr">2</xref>).
</p>
